CUREVAC NV (5CV.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:5CV - NL0015436031 - Common Stock
3.892 EUR
+0.01 (+0.36%)
We assign a fundamental rating of 4 out of 10 to 5CV. 5CV was compared to 83 industry peers in the Biotechnology industry. 5CV has only an average score on both its financial health and profitability. 5CV is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- In the past year 5CV was profitable.
- 5CV had a negative operating cash flow in the past year.
- In the past 5 years 5CV reported 4 times negative net income.
- In multiple years 5CV reported negative operating cash flow during the last 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of 11.31%, 5CV belongs to the top of the industry, outperforming 84.34% of the companies in the same industry.
- 5CV has a Return On Equity of 14.79%. This is amongst the best in the industry. 5CV outperforms 84.34% of its industry peers.
- 5CV's Return On Invested Capital of 14.12% is amongst the best of the industry. 5CV outperforms 87.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.31% | ||
| ROE | 14.79% | ||
| ROIC | 14.12% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With an excellent Profit Margin value of 182.11%, 5CV belongs to the best of the industry, outperforming 98.80% of the companies in the same industry.
- With an excellent Operating Margin value of 212.01%, 5CV belongs to the best of the industry, outperforming 98.80% of the companies in the same industry.
- With an excellent Gross Margin value of 93.01%, 5CV belongs to the best of the industry, outperforming 86.75% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 212.01% | ||
| PM (TTM) | 182.11% | ||
| GM | 93.01% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- 5CV has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- 5CV has about the same amout of shares outstanding than it did 1 year ago.
- The number of shares outstanding for 5CV has been increased compared to 5 years ago.
- 5CV has a better debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 4.17 indicates that 5CV is not in any danger for bankruptcy at the moment.
- 5CV's Altman-Z score of 4.17 is fine compared to the rest of the industry. 5CV outperforms 75.90% of its industry peers.
- 5CV has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
- 5CV's Debt to Equity ratio of 0.03 is fine compared to the rest of the industry. 5CV outperforms 69.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.17 |
ROIC/WACC1.96
WACC7.19%
2.3 Liquidity
- 5CV has a Current Ratio of 3.70. This indicates that 5CV is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 3.70, 5CV is in the better half of the industry, outperforming 69.88% of the companies in the same industry.
- A Quick Ratio of 3.69 indicates that 5CV has no problem at all paying its short term obligations.
- With a decent Quick ratio value of 3.69, 5CV is doing good in the industry, outperforming 73.49% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.7 | ||
| Quick Ratio | 3.69 |
3. Growth
3.1 Past
- 5CV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.83%, which is quite impressive.
- Looking at the last year, 5CV shows a very negative growth in Revenue. The Revenue has decreased by -86.98% in the last year.
- The Revenue has been growing by 98.42% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)20.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.33%
Revenue 1Y (TTM)-86.98%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-89.04%
3.2 Future
- Based on estimates for the next years, 5CV will show a very negative growth in Earnings Per Share. The EPS will decrease by -22.50% on average per year.
- Based on estimates for the next years, 5CV will show a very negative growth in Revenue. The Revenue will decrease by -11.14% on average per year.
EPS Next Y-163.99%
EPS Next 2Y-61.18%
EPS Next 3Y-28.72%
EPS Next 5Y-22.5%
Revenue Next Year-84.14%
Revenue Next 2Y-55.71%
Revenue Next 3Y-30.85%
Revenue Next 5Y-11.14%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 6.71 indicates a rather cheap valuation of 5CV.
- Based on the Price/Earnings ratio, 5CV is valued cheaply inside the industry as 95.18% of the companies are valued more expensively.
- When comparing the Price/Earnings ratio of 5CV to the average of the S&P500 Index (27.47), we can say 5CV is valued rather cheaply.
- The Forward Price/Earnings Ratio is negative for 5CV. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.71 | ||
| Fwd PE | N/A |
4.2 Price Multiples
- 5CV's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. 5CV is cheaper than 96.39% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 2.92 |
4.3 Compensation for Growth
- 5CV's earnings are expected to decrease with -28.72% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-61.18%
EPS Next 3Y-28.72%
5. Dividend
5.1 Amount
- No dividends for 5CV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:5CV (1/5/2026, 7:00:00 PM)
3.892
+0.01 (+0.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-24 2025-11-24/bmo
Earnings (Next)04-08 2026-04-08/amc
Inst Owners10.45%
Inst Owner ChangeN/A
Ins Owners0.09%
Ins Owner ChangeN/A
Market Cap876.36M
Revenue(TTM)70.74M
Net Income(TTM)128.82M
Analysts74.55
Price Target4.02 (3.29%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)557.4%
Min EPS beat(2)-39.67%
Max EPS beat(2)1154.47%
EPS beat(4)2
Avg EPS beat(4)282.88%
Min EPS beat(4)-39.67%
Max EPS beat(4)1154.47%
EPS beat(8)3
Avg EPS beat(8)141.82%
EPS beat(12)5
Avg EPS beat(12)87.36%
EPS beat(16)8
Avg EPS beat(16)76.39%
Revenue beat(2)1
Avg Revenue beat(2)149.77%
Min Revenue beat(2)-96.47%
Max Revenue beat(2)396.01%
Revenue beat(4)2
Avg Revenue beat(4)82.72%
Min Revenue beat(4)-96.47%
Max Revenue beat(4)396.01%
Revenue beat(8)5
Avg Revenue beat(8)103.01%
Revenue beat(12)5
Avg Revenue beat(12)58%
Revenue beat(16)8
Avg Revenue beat(16)71.24%
PT rev (1m)-2.38%
PT rev (3m)-4.19%
EPS NQ rev (1m)0%
EPS NQ rev (3m)404.74%
EPS NY rev (1m)9.31%
EPS NY rev (3m)2.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)34.82%
Revenue NY rev (1m)19.7%
Revenue NY rev (3m)20.12%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.71 | ||
| Fwd PE | N/A | ||
| P/S | 12.39 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.01 | ||
| P/tB | 1.04 | ||
| EV/EBITDA | 2.92 |
EPS(TTM)0.58
EY14.9%
EPS(NY)-0.44
Fwd EYN/A
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)-0.53
OCFYN/A
SpS0.31
BVpS3.87
TBVpS3.76
PEG (NY)N/A
PEG (5Y)N/A
Graham Number7.11
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.31% | ||
| ROE | 14.79% | ||
| ROCE | 16.62% | ||
| ROIC | 14.12% | ||
| ROICexc | 26.37% | ||
| ROICexgc | 27.79% | ||
| OM | 212.01% | ||
| PM (TTM) | 182.11% | ||
| GM | 93.01% | ||
| FCFM | N/A |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.18 | ||
| Cap/Depr | 28.09% | ||
| Cap/Sales | 7.01% | ||
| Interest Coverage | 66.45 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.7 | ||
| Quick Ratio | 3.69 | ||
| Altman-Z | 4.17 |
F-Score3
WACC7.19%
ROIC/WACC1.96
Cap/Depr(3y)242.45%
Cap/Depr(5y)397%
Cap/Sales(3y)81.47%
Cap/Sales(5y)93.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.33%
EPS Next Y-163.99%
EPS Next 2Y-61.18%
EPS Next 3Y-28.72%
EPS Next 5Y-22.5%
Revenue 1Y (TTM)-86.98%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-89.04%
Revenue Next Year-84.14%
Revenue Next 2Y-55.71%
Revenue Next 3Y-30.85%
Revenue Next 5Y-11.14%
EBIT growth 1Y13.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-158.29%
EBIT Next 3Y-29.43%
EBIT Next 5Y10.78%
FCF growth 1Y62.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y56.06%
OCF growth 3YN/A
OCF growth 5YN/A
CUREVAC NV / 5CV.DE FAQ
Can you provide the ChartMill fundamental rating for CUREVAC NV?
ChartMill assigns a fundamental rating of 4 / 10 to 5CV.DE.
What is the valuation status of CUREVAC NV (5CV.DE) stock?
ChartMill assigns a valuation rating of 3 / 10 to CUREVAC NV (5CV.DE). This can be considered as Overvalued.
Can you provide the profitability details for CUREVAC NV?
CUREVAC NV (5CV.DE) has a profitability rating of 5 / 10.
What are the PE and PB ratios of CUREVAC NV (5CV.DE) stock?
The Price/Earnings (PE) ratio for CUREVAC NV (5CV.DE) is 6.71 and the Price/Book (PB) ratio is 1.01.
How financially healthy is CUREVAC NV?
The financial health rating of CUREVAC NV (5CV.DE) is 6 / 10.